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Abstract
The induction of relatively weak immunity by DNA vaccines in humans can be largely attributed to the low efficiency of
transduction of somatic cells. Although formulation with liposomes has been shown to enhance DNA transduction of
cultured cells, little, if any, effect is observed on the transduction of somatic tissues and cells. To improve the rate of
transduction, DNA vaccine delivery by gene gun and the recently developed electroporation techniques have been
employed. We report here that to circumvent requirement for such equipment, amiloride, a drug that is prescribed for
hypertension treatment, can accelerate plasmid entry into antigen presenting cells (APCs) both in vitro and in vivo. The
combination induced APCs more dramatically in both maturation and cytokine secretion. Amiloride enhanced development
of full CD8 cytolytic function including induction of high levels of antigen specific CTL and expression of IFN-
c+perforin+granzymeB+ in CD8+ T cells. Thus, amiloride is a facilitator for DNA transduction into host cells which in turn
enhances the efficiency of the immune responses.
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Introduction
DNA vaccination first proved to be effective in the 1990s when
it was used to treat viral infection [1,2]. It was shown to favor
cellular immune responses in contrast to recombinant subunit
vaccines that favor humoral responses [3,4]. However, unsuccess-
ful clinical trials indicated that DNA vaccines suffered from low
efficiency in transducing host cells via syringe-based delivery [5]. A
great improvement in transduction was obtained by using DNA
plasmid that was coated on gold pellets and bombarded into
somatic cells by using gene gun technology [6,7,8,9]. Recently,
even higher transduction efficiency has been achieved by the use of
in vivo electroporation devices [10,11,12,13]. Both approaches
require special equipment and may cause some discomfort in
vaccinees [14]. Although there have been many other approaches
to enhance efficiency, including the use of adjuvants, cytokines,
nanoparticles etc., few approaches have focused on enhancing
transduction of somatic cells. The mystery of why liposome
delivery of DNA into cultured cells is very efficient, but the same
delivery into cells in vivo is inefficient has not been completely
solved. Although some chemical compounds, such as Bupivacain
[15], have been shown to enhance DNA entry into muscle when
given in pretreatment, directly enhancing DNA uptake into
somatic cells remains a challenge.
Amiloride, an inhibitor of the Na/K pump of cellular
membranes [16], has been routinely used as an inhibitor of
macropinocytosis [17]. Due to this effect, it has been clinically
prescribed to treat hypertension[18]. No report has been made of
an effect on DNA plasmid transduction of cells or tissues or of
subsequent effects on the immune responses.
Here we report that amiloride effectively accelerates DNA entry
into cells in vitro and in vivo, with subsequent adjuvancity on both
innate and adaptive responses, particularly on antigen specific
CD8
+ CTL responses. Therefore, amiloride might be further
developed as a new facilitator for DNA vaccines.
Results
Amiloride accelerates DNA entry into APC
We initially observed that amiloride enhanced DNA entry into
the JAWSII DC cell line when we performed endocytosis
inhibition assays (Data not shown). This phenomenon was again
observed with both a macrophage cell line (RAW264.7) and
dendritic cell lines (JAWSII and DC2.4). When the cells were pre-
treated with 1 mM amiloride for 1 h, we observed that uptake of
Cy5-labeled pEGFP plasmids was significantly enhanced within
2 hrs and the cells expressed a significantly higher level of GFP
after 3d culture compared with the un-treated cells. This high level
of expression was similar to that seen when DNA was delivered
with liposomes (Fig. 1).
Although amiloride could facilitate DNA plasmid entry into
cultured cells, we considered that it might not work with somatic
cells. To test this in vivo, Cy5-labeled pEGFP plasmid, with or
without amiloride, was injected into the hind footpads of C57Bl/6
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hmice. After 4 hrs, draining lymph nodes were collected and Cy5
+
cells were analyzed by FACS (Fig. 2A). The inguinal lymph nodes
from the un-injected side were also collected as negative controls.
The percentage of Cy5-plasmid
+ cells in LN was increased with
10 mM amiloride, peaked at 100 mM, but decreased at 1 mM
(Fig. 2B). We next analyzed whether transfected cell subset was
affected by amiloride. Data showed that as amiloride accelerated
cell transfection, cell subset remain unaltered: the majority of Cy5
+
cells were CD11c
+ and CD11b
+, suggesting dendritic cells and
macrophages, and ,10% was positive for B220, a B cell marker;
but few were T cells since only a background signal was obtained
after CD3
+ staining (Fig. 2C). The facilitated cell entry also
resulted in higher levels of transduced gene expression as
demonstrated by the higher GFP intensities after 24 h, and
similar transfection of cell subsets. (Fig. 2D and 2E).
DNA entry into cells was previously reported to be through
endocytosis [19,20,21]. To examine which endocytic pathway
mediated this entry, we used specific endocytosis inhibitors to see
their effects. Adding either MbCD, an inhibitor of lipid-raft
dependent endocytosis, or fillipin, an inhibitor of caveolae-
dependent endocytosis, reduced the amiloride-mediated DNA
entry and gene expression. The amiloride-mediated DNA entry
could be completely abolished by MbCD plus fillipin in
RAW264.7 cells (Fig. S1A, B). Similar inhibition was also observed
in both JAWSII and DC2.4 cell lines (Fig. S1C, D, E, F). These
results suggest that amiloride mediated DNA entry is through both
lipid-raft- and caveolae- dependent endocytosis in vivo.
Amiloride enhances innate immunity
Because amiloride facilitated the entry of DNA into, and
subsequent higher gene expression in antigen presenting cells
(APCs), we asked if this could positively affect innate immune
responses. To test this notion, after verification of amiloride alone
has no effect on innate immune response (Fig. S2), we used a HBV
DNA vaccine, pcD-52, encoding HBsAg and conjugated with Cy5
as a model. Higher levels of expression of CD40, CD80 and CD86
were obtained on cultured RAW264.7 cells (Fig. 3A, B and Fig.
S3A), suggesting that amiloride treatment could increase the level
of maturation for this macrophage cell. Consistent with enhanced
maturation, we also observed that higher levels of expression of
TNF and IFN-c were induced with amiloride treatment than
without treatment (Fig. 3C). Similar enhanced maturation status
was reached in both dendritic cell lines, DC2.4 and JAWSII,
although there were some differences in expression levels for the
pro-inflammatory cytokines (Fig. 3D, E, F, G and Fig. S3B, C).
Since cell lines can have skewed cytokine profiles caused by
prolonged culture, we next tested the treatments with freshly
isolated APCs, either peritoneal macrophages or splenic dendritic
cells. Both cell types showed higher expression of maturation
markers and more pro-inflammatory cytokine secretion when the
cells were treated with pcD-S2 plus amiloride than with pcD-S2
alone (Fig. 3H, I, J, K and Fig. S3D, E).
To confirm amiloride’s up-regulation of innate immunity in vivo,
we injected pEGFP into right hinder footpad, with or without
amiloride, and analyzed maturation markers of transduced (GFP
+)
cells. Again, data showed CD80 and CD86 were up-regulated by
amiloride treatment (Fig. 3L).
Amiloride enhances immune responses including strong
CMI for pcD-S2 DNA vaccine
Enhancement of innate responses may affect adaptive
responses. To test this, plasmid DNA, pcD-S2, with or without
Figure 1. Amiloride facilitates plasmid entry in vitro. Cy5-pEGFP entry into cell lines with or without 1 mM amiloride was analyzed after 2 h and
is shown as the percentage of cells that were Cy5
+. Expression of GFP was analyzed at day 3 and is shown as percentage of EGFP
+Cy5
+, on RAW264.7
(A, B, C), JAWSII (D, E), and DC2.4 (F, G). Data represent one of three independent experiments.
doi:10.1371/journal.pone.0033015.g001
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Antibody against HBsAg was increased in the amiloride+ group
compared to groups given pcD-S2 alone and the effect was dose-
dependent (Fig. 4B). The DTH reaction against HBsAg was also
increased more in the pcD-S2 plus amiloride groups than those
given pcD-S2 alone (Fig. 4C). Both experiments showed that
1 mM of amiloride was the most effective dose for in vivo
treatment.
DTH reflects cell mediated immunity (CMI), of which an
important component is the CD8+ cytolytic T lymphocyte (CTL).
To explore if amiloride could also influence CTL, CD8+ T cells
from immunized mice were purified as effector cells, and naı ¨ve
C57 splenocytes were treated with HBsAg peptide S208–215 and
subsequently labeled with CFSE for use as target cells. The cells
were mixed at different effector/target ratios. After 3 days culture
at E:T ratio of 10:1, 60 percent of target cells were lysed in the
amiloride plus pcD-S2 group, significantly higher than ,30% lysis
in the pcD-S2 alone group (Fig. 4D). Furthermore, in vivo CTL
assay was performed by using peptide treated CFSE labeled target
cells that were transferred into immunized syngeneic mice via i.v.
injection. A stronger cytolytic activity was achieved in the
amiloride plus pcD-S2 group compared with the untreated
counterparts (Fig. 4E).
This antigen specific killing was further demonstrated in the use
of liver cells from Alb1-HBV mice, liver-specific HBsAg transgenic
mice, as target cells in the in vitro test and in the in vivo test
(Fig. 4F, G). Consistent with previous results, a higher level of CTL
was achieved in the amiloride plus pcD-S2 group compared to the
controls.
Amiloride increases triple positive CD8 T cells
IFN-c, perforin and granzyme B are the essential components of
CTL that contribute viral clearance [22,23,24,25,26]. The
presence of these multiple factors within a single CD8 T cell,
creating a multi-functional effector, has been documented as a
more powerful anti-viral effector system [25,27,28,29]. To test if
amiloride has an adjuvant effect on multi-functional CTL, we
performed a simultaneous FACS assay of multiple cell markers
including IFN-c, perforin and granzyme B to differentiate for
cytolytic CD8+ T effectors (Fig. S4A). Compared with pcD-S2
immunization alone, immunization with amiloride plus pcD-S2
didn’t increase the frequency of CD8+ T effectors responding to
specific antigen (Fig. 5A). However it did increase the proportion
of triple positive CD8+ T effectors within the responding CD8+
population (Fig. 5B, C and Fig. S4B). Furthermore, the increased
proportion of triple positive cells could also be observed in an
HBsAg-stimulated CD8 response (Fig. 5D), suggesting a more
general boost by amiloride of CD8 T cell cytotoxity against HBV.
Taken together, the results indicated that there would be stronger
and more efficient killing of target cells.
To further demonstrate that the increase of triple positive CD8
T effectors was likely to be due to effects on APCs, peritoneal
macrophages and spleen dendritic cells were collected and treated
with pcD-S2 with or without amiloride, then co-cultured for 5
days with purified CD8 T cells from HBsAg immunized mice.
During co-culture, epitope S208–215 was used to re-stimulate.
Results showed that amiloride significantly increased the percent-
age of S208–215 specific triple positive CD8 T effectors in the co-
culture system, both with macrophages (Fig. 5E and Fig. S4C) and
DCs (Fig. 5F and Fig. S4D).
Discussion
Here we report that amiloride, a previous prescribed drug for
hypertension, could facilitate plasmid entry into antigen presenting
cells (APCs), both in vitro and in vivo. Enhanced antigen
expression in APC was accompanied by accelerated maturation
and cytokine secretion. This led to enhanced adaptive immune
responses as evidenced at the level of antigen specific CD8 T
Figure 2. Amiloride accelerates plasmid entry in vivo. Naı ¨ve C57 mice (n=3) were immunized with Cy5-pEGFP s.c. in hind footpad with (right
side) or without (left side) amiloride. Lymph node cells were collected after 4 h (Cy5
+ cells) and after 24 h (GFP
+ cells) and examined for proportion (B,
D) and subtype (C, E) of stained cells from both draining and control lymph nodes. * in B and D, statistical significance between control and draining
lymph nodes in all treated groups.
doi:10.1371/journal.pone.0033015.g002
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effective antigen specific CTL, and the higher expression of
IFN-c
+perforin
+granzymeB
+ in the antigen specific CD8
+ T cells.
Therefore, this study demonstrates that amiloride is a facilitator for
DNA transduction into host cells, which in turn enhances the
efficiency of immune responses.
When we first observed amiloride facilating plasmid DNA entry
into cell lines (Fig. 1), we were interested in which uptake pathway
Figure 3. Amiloride enhances APC maturation and innate cytokine secretion. pcD-S2 at 10 mg/ml with or without 1 mM of amiloride was
added in cell culture for stimulation. Surface maturation markers CD40, CD80, CD83, CD86, MHC-I, MHC-II and secreted innate cytokines IL-6, TNF-a,
IL-1b, IFN-c in supernatant, were tested at day 3 on RAW264.7 (A, B, C), JAWSII (D, E), DC2.4 (F, G), peritoneal macrophage (H, I) and spleno-DC (J, K).
pEGFP was injected into footpad with or without amiloride, 24 h later, surface maturation markers were analyzed on GFP+ cells from draining LN (L).
Shown is one of three independent experiments with similar results, analyzed based on Cy5+ (A, D, F), F4/80+ (H), CD11c+ (J) or GFP+ (L)cells. For
peritoneal macrophage and spleno-DC, n=3. * and ** indicate significant difference between +/2 amiloride.
doi:10.1371/journal.pone.0033015.g003
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macropinocytosis inhibitor [16] and yet it facilitated DNA plasmid
entering cells, other endocytic pathways were implied. Since
inhibition of two other pathways of endocytosis by use of their
respective inhibitors reduced the level of DNA plasmid entry, we
deduce that lipid-raft- and caveolae-dependent endocytosis may be
the main pathways involved (Fig. S1). However, amiloride has
been found to affect the polymeric formation of cytoskeletons,
involving actins or tubulins, and directly blocks the epithelial
sodium channel [30,31,32,33,34]. Hence mechanisms other than
the endocytosis might also be involved in the DNA entry
facilitation.
Various strategies have been developed to transfect plasmid into
cell lines in vitro [35,36], including liposome-based transduction,
but few has been successfully adapted in vivo [37,38]. Higher
transducing efficiency has been achieved by the use of in vivo
electroporation and gen gun delivery [10,11,12,13], however,
those require special equipment and may cause some discomfort in
vaccinees [14]. Therefore, since amiloride facilitated plasmid entry
and expression in vitro, simple co-injection of amiloride with
plasmid DNA was tested for its in vivo effects. Co-injection in vivo
facilitated plasmid into APCs and expression of the encoded gene
(Fig. 2). This demonstration of both in vitro and in vivo effects
suggests benefits for both DNA vaccine technology in general as
well as other applications such as gene and RNAi therapies [39].
There is also the possibility of combining amiloride and
electroporation in vivo to improve DNA vaccine efficacy.
Naked DNA vaccine is routinely administrated by injection
intramuscularly to take advantage of the large volume of muscle
fibers to take in DNA and so to result in higher expression of the
Figure 4. Amiloride enhances adaptive immunity against HBV S2. Naı ¨ve C57 mice were immunized s.c. with pcD-S2 at various
concentrations with or without amiloride in the hind footpad four times using the immunization scheme as shown (A). Seven days after the last
immunization, animals (n=3) were used to test anti-S2 IgG antibody titer (B) and delayed hypersensitivity (DTH) response after re-stimulation with
1 mg sAg s.c. in a hind footpad for 24 h (C). PBS was added as negative control. *, statistical significance among all groups. Another 3 animals were
used to test HBV S208–215 specific lysis in vitro (D) and in vivo (E). Hepatocytes from HBV Alb1 trangenic mice were used as targets mixed with
effectors from the immunized mice, or transferred into the immunized mice before the analysis of specific lysis in vitro (F) and in vivo (G). *, statistical
significance between +/2 amiloride.
doi:10.1371/journal.pone.0033015.g004
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presenting cells, and antigen expressed in muscle provides an
inefficient stimulus to the immune responses compared to
expression in APCs [40,41,42,43,44]. Lymph node injection
technology has previously been demonstrated to enhance DNA
vaccine induced immune response by 100-fold by favoring antigen
expression in APCs [11] and the higher antigen expression
correlated with higher levels of maturation of the transduced APCs
[45]. The increased loading of epitopes from expressed antigen
onto MHC presumably provided more efficient stimulation by the
APCs to produce higher levels of pro-inflammatory cytokines [46].
Our findings are consistent with this view. Amiloride facilated
plasmid entry and expression in APCs, thereby inducing higher
levels of maturation and cytokine secretion in these treated cells
(Fig. 3), whereas amiloride alone wasn’t capable of promoting
APCs’ maturation (Fig. S2). These matured APCs could then
affect adaptive immune responses so that higher levels of antibody
production and cell-mediated responses were obtained as depicted
in Figure 4. Antigen specific CTL killing can directly contribute to
immunological function against, or clearing of chronic viral
Figure 5. Amiloride increases the frequency of triple positive CD8 T cells. Splenocytes from mice immunized with pcD-S2 with or without
amiloride (n=3) were re-stimulated in vitro with 10 mg/ml S208–215 for 12 h (A-C), or 10 mg/ml HBsAg for 24 h (D), then cytokine secretion was
blocked by monensin for 6 h. PMA or Ionomycin stimulating splenocyte of pcD-S2 immunized mice was added as positive controls. Cells stained with
anti-CD3 and anti-CD8 were gated and then used for intracellular staining with single or multiple fluorescent-labeled antibodies. A shows the
proportion of responsive cells in the total CD8
+ T cells with or without amiloride treatment. These responsive cells were designated as either IFN-c
+,
perforin
+, or granzymeB
+ cells. B shows the cytokine expression pattern in the responsive CD8 T cells with or without amiloride treatment. C shows
the dose dependent effects of amiloride on the frequency of (IFN-c
+perforin
+granzymeB
+) triple positive cells. D shows the change in frequency of
triple positive cells in response to HBsAg re-stimulation. The change in frequency of triple positive cells after co-culture with peritoneal macrophages
followed by re-stimulation with S208–215 (E), or with spleno-DC (F) are also shown. Data represent three independent experiments with similar
results.
doi:10.1371/journal.pone.0033015.g005
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activated CD8 T cells were similar, (Fig. 5A), inclusion of
amiloride induced significantly more CD8 CTL (Fig. 4D, 4E,
4F, 4G). The discrepancy was due to different functional CD8 T
cells being induced. Thus the amiloride-induced CD8 CTL
contained higher proportions of IFN-g
+Perforin
+GranzymeB
+
(triple positive) cells (Fig. 5B, 5C, 5D). This differential induction
has been further demonstrated by an in vitro study in which
antigen+amiloride treated macrophages or splenocyte-DC had
increased ability to convert antigen primed CD8 T cells into triple
positive CD8+ T cells (Fig. 5E, F). These results indicated that
amiloride is not only a facilitator for DNA entry and expression,
but also a very important adjuvant to affect adaptive immune
responses.
Thus, amiloride, a prescription drug for hypertension, could
facilitate plasmid transduction of antigen presenting cells (APCs)
both in vitro and in vivo. The transduced APCs could undergo
enhanced maturation and cytokine production resulting in
dramatically enhanced adaptive immune responses. Amiloride
thus induced multi-functional CD8 CTL, which may lead to the
development of novel therapeutic vaccination strategies against
chronic infectious diseases. This facilitation by amiloride may be
useful not only for DNA vaccination, but also for non-viral vector
based gene therapy.
Materials and Methods
Animal, cell line and reagents
Adult female C57BL/6 mice (8–10 week of age) were from
Beijing Vital Laboratory Animal Technology Company, Ltd.
(Beijing, China) and kept in SPF condition. HBV sAg transgenic
mice Alb1-HBV and IFN-c
2/2 mice (B6.129S7-Ifngtm1Ts/J)
were purchased from Jackson Lab (Main, USA). All animal
experiments were approved by the Committee of Experiment
Animals of China Agricultural University. RAW264.7, JAWSII
and DC2.4 were purchase from ATCC (VA, USA). Lipofactami-
ne
TM2000 was purchased from Invitrogen (CA, USA). HBsAg was
obtained from NCPC Ltd. (Hebei, China). S208–215 peptide was
synthesized by Scipeptide Ltd. (Shanghai, China). pcD-S2 was
cloned and reserved in lab [47]. All antibodies for DC maturation
(anti-CD40-PE, anti-CD80-PE, anti-CD83-PE, anti-CD86-PE,
anti-MHC I-PE, anti-MHC II-PE), cell subset identification
(anti-CD11c-FITC, anti-CD11c-APC, anti-CD11b-FITC, anti-
CD11b-APC, anti-B220-PE, anti-CD3-FITC, anti-CD3-APC)
and multi-color flow cytometry (anti-CD3-APC-Cy7, anti-CD8-
FITC, anti-IFN-c-PerCP-Cy5.5, anti-perforin-PE and anti-gran-
zymeB-PE-Cy7) were purchased from eBioscience (CA, USA).
Flexset kits for IL-6, TNF, IL-1b and IFN-c were purchased from
BD Biosciences (USA).
Cell culture and inhibitor treatment
RAW264.7 and DC2.4 were cultured in DMEM/10%FCS,
and JAWSII was cultured in DMEM/10%FCS with GM-CSF
(1000 U/ml, Peprotech, USA). Amiloride (Sigma-Aldrich, USA)
was prepared at 10 mM as stock solution and diluted to 1 mM,
100 uM and 10 uM in DMEM medium before treatments. After
medium was removed, cells were treated with amiloride, MbCD
(5 mM, Sigma) or Fillipin (10 mg/ml, Sigma) at 37uC for 1 h. The
cells were treated with LPS (10 ng/ml, Sigma) or 10 mg/ml DNA
in DMEM at 37uC for 0.5 h and washed 3 times. The culture
medium was added back for continuing culture.
Peritoneal macrophage was washed from the murine peritoneal
cavity with 10 ml PBS, rinsed and tested for F4/80 positivity. The
F4/80+ macrophages were routinely present at a frequency of
,50–70%. Spleen dendritic cells were prepared from plate-
adhesive cells and purified with Miltenyi DC purification kit
(Miltenyi Biotec, Gladbach, Germany). Cells were treated and
cultured for 3 days for assessment of innate response.
Plasmid preparation and fluorescence conjugation
pEGFP (Clontech, USA) and pcD-S2 plasmid were made as
midi-preps from DH5a culture, purified by EndoFree Plasmid
Maxi Kit (Qiagen, Germany) and endotoxin was below 10 EU/
mg by LAL test. Cy5 was conjugated to plasmid with Mirus Label
IT Kit (Mirus, USA) according to the manufacturer’s instruction.
Plasmid Entry Test
For in vitro testing, cell lines were treated with 1 mM amiloride
and 10 mg/ml Cy5 conjugated pEGFP was added. Lipo2000 was
added as positive control. Cy5+ cells were analyzed for plasmid
entry at 2 hours later and GFP+ cells were analyzed for expression
on day 2. For in vivo facilitation, 20 mg Cy5-pEGFP in PBS was
injected into C57/B6 mice right hind footpad +/2 amiloride.
Both inguinal lymph nodes were collected for assessment of Cy5+
cell proportion 4 h later, or 24 h later for GFP expression. For
induction of immune responses, 20 mg pcD-S2 in PBS was injected
into hind footpad +/2 amiloride 4 times at 2-week intervals.
In vitro and in vivo CTL
In vitro CTL assay was performed as reported, with slight
modifications [48]. Briefly, CD8+ T cells were purified from the
splenocytes of immunized mice with a CD8 purification kit (R&D
systems, USA) and used as effecter cells. Splenocytes from naı ¨ve
C57BL/6 mice were pulsed with 10
26 M of HBsAg CTL peptide
S208–215 [49] and labeled with 30 mM CFSE for use as target
cells. The same naı ¨ve splenocytes without peptide pulse were
labeled with 10 mM CFSE as control. Effecters and target cells
were mixed at ratios of 10:1, 1:1 and 1:10. After 3 days in culture,
lysis of target cells was analyzed by FACSCalibur (BD Biosciences,
USA). Specific lysis was calculated as (12target cells/control
cells)6100%.
In vivo CTL assay was performed as described previously [47],
using S208–215 peptide and splenocytes from naı ¨ve C57BL/6
mice that had been labeled with 30 mM CFSE as target cells.
Splenocytes without peptide were labeled 10 mM CFSE as control.
The target and control cells were mixed in a 1:1 ratio and i.v.
injected into immunized mice at 2610
7 total cells per mouse.
Splenocytes of injected mice were collected and analyzed 12 h
later.
For Alb1-HBV mice, single cell suspensions were prepared from
liver and the hepatic cells were used as target cells in in vitro and in
vivo CTL assays as described above. For in vivo CTL assay, 10%
CFSE cells were in spleen 12 h after transfer. Data was acquired
until CFSE
low (10 mM) cells reached 10
4.
Multi-color Flow Cytometry
A multi-color antibody panel was set up with anti-CD3, anti-
CD8, anti-IFN-c, anti-perforin and anti-granzyme B. Splenocytes
were re-stimulated in vitro by sAg for 24 h or S208–215 for 12 h,
then after monensin block for 6 h, splenocyte were fixed and
stained. Data was collected with BD Aria I and analyzed with
Flowjo (Tree Star, Ashland, USA) and Grapher (Golden Software,
USA).
pcD-S2 (10 mg/ml) with or without 100 mM amiloride was used
to treat peritoneal macrophages or spleen dendritic cells in culture
for 2 days. At day 3, purified CD8 T cells (R&D systems, USA)
were added into the APC cultures at APC : T cell ratios of 1:5, 1:2
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stimulated overnight with S208–215 (10 mg/ml) or PMA+Iono-
mycin as positive controls. The re-stimulated cells were assayed
after multi-color staining as mentioned above.
Statistics
Data were analyzed using the one-tail Student’s t-test (Fig. 3,
4E, 4G, 5D, E, F,), one-way ANOVA for more than 2 groups
(Fig. 1, 2B, 4C, 5C, Fig. S1), or two-way ANOVA (Fig. 4D, 4F).
Differences were considered to be statistically significant with
p,0.05 for * and p,0.01 for **.
Supporting Information
Figure S1 Amiloride’s acceleration of plasmid entry is
lipid-raft and caveolae-dependent. Lipid-raft inhibitor,
MbCD, or caveolae inhibitor, fillipin was added with amiloride
to block endocytosis pathways on cell lines, RAW264.7 (A, B),
JAWSII (C, D), and DC2.4 (E, F). Then Cy5-pEGFP was added
for assay of entry in 2 h and expression in 3 days. Shown is one of
three independent experiments with similar results.
(TIF)
Figure S2 Amiloride alone does not promote APC
matuation. Surface maturation markers CD40, CD80, CD83,
CD86, MHC I and/or MHC II were tested at day 3 on
RAW264.7 (A), JAWSII (B), DC2.4 (C), peritoneal macrophage
(D) and spleno-DC (E), with or without 1 mM amiloride
treatment. Shown is one of three independent experiments with
similar results. For peritoneal macrophage and spleno-DC, n=3. *
and ** indicate significant difference between +/2 amiloride.
(TIF)
Figure S3 Amiloride enhances APC maturation. Surface
maturation markers CD40, CD80, CD83, CD86, MHC I and/or
MHC II were tested at day 3 on RAW264.7 (A), JAWSII (B),
DC2.4 (C), peritoneal macrophage (D) and spleno-DC (E), with or
without 1 mM amiloride treatment. MFI data were showed.
Shown is one of three independent experiments with similar
results. For peritoneal macrophage and spleno-DC, n=3. * and **
indicate significant difference between +/2 amiloride.
(TIF)
Figure S4 Amiloride increases multi-cytokine CD8 T
cells. Re-stimulated, monensin blocked CD8 T cells were stained
and analyzed with gate hierarchy (A). Pie graph of cytokine
expression from each mouse was showed, splenocytes re-
stimulated with 10 mg/ml S208–215 for 12 h (B), or co-cultured
with peritoneal macrophages followed by re-stimulation with
S208–215 (C), or with spleno-DC (D) are also shown. Data
represent three independent experiments with similar results.
(TIF)
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